ACM
LGND icon

Aster Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Aster Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19
Closed -$3.59K – 1123
2025
Q4 		$3.59K Buy
+19
New +$3.65K ﹤0.01% 914

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Aster Capital Management's LGND Position: Q1 2026 in Review

Aster Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 19 shares — an estimated $3.59K sold.

Aster Capital Management first reported a position in LGND in Q4 2025 and held it in 1 quarter. The position peaked at $3.59K in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Aster Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 19 Ligand Pharmaceuticals shares in Q1 2026, an estimated $3.59K.
  • Aster Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Aster Capital Management's Ligand Pharmaceuticals position peaked at $3.59K in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.